Diasorin SpA (EUR)
DIA
Overview
Key Information
Legal Documents
Financials
Overview
| Sector | Healthcare |
| Industry | - |
| Day Range | 161.00 | 162.70 |
| 52-Wk Range | - | - |
| Last Close | 162.60 |
| Mkt Cap (m) | 8,906.44 |
| Dividend yield | 0.58 |
| ISIN | IT0003492391 |
| Volume | 185,002.00 |
| Exchange Venue | MIL |
Company Profile
Diasorin SpA is engaged in the development, manufacture and distribution ofimmunodiagnostics and molecular diagnostics tests.
Key Information
| Price/Earning | 42.22 |
| Price/Book | 9.83 |
| Price/Sales | 11.26 |
| P/CF | 34.14 |
| Rev Growth (3 year avg) | - |
| EPS Growth (3 year avg) | - |
| Operating Margin % | - |
| Net Margin % | - |
| Return on Equity | - |
| Debt/Equity | - |
Financials
Income Statement
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
| Revenue (m) | 499.18 | 569.31 | 637.49 | 669.20 | 706.32 | - |
| Operating Income (m) | 156.07 | 177.94 | 197.56 | 209.85 | 222.46 | - |
| Net Income (m) | 100.42 | 112.38 | 139.88 | 158.13 | 175.74 | - |
| Basic EPS | 1.83 | 2.05 | 2.54 | 2.85 | 3.21 | - |
| Avg. Diluted Shares Outstanding (m) | 54.88 | 55.09 | 55.00 | 55.51 | 54.92 | - |
Balance Sheet
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
| Current Assets (m) | 494.33 | 395.38 | 482.44 | 414.86 | 530.76 | - |
| Non Current Assets (m) | 213.57 | 473.24 | 460.48 | 491.08 | 532.79 | - |
| Total Assets (m) | 707.91 | 868.62 | 945.72 | 905.94 | 1,063.55 | - |
| Current Liabilities (m) | 82.44 | 131.88 | 141.12 | 138.45 | 122.48 | - |
| Total Liabilities (m) | - | - | - | - | - | - |
| Total Equity (m) | 586.81 | 662.82 | 741.42 | 704.73 | 848.62 | - |
Cash Flows
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
| Operating Cash Flows (m) | 138.45 | 165.60 | 167.44 | 209.88 | 232.67 | - |
| Capital Expenditure (m) | -32.05 | -37.43 | -42.48 | -52.79 | -55.79 | - |
Figures are quoted in EUR unless stated otherwise
-
No change
€
162.60
Last Price
© 2019 MeDirect Bank (Malta) plc. All rights reserved.